A citation-based method for searching scientific literature

Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Rolf Hultcrantz, Stergios Kechagias. J Hepatol 2017
Times Cited: 485







List of co-cited articles
800 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
54

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Paul Angulo, David E Kleiner, Sanne Dam-Larsen, Leon A Adams, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Jill C Keach, Heather D Lafferty, Alisha Stahler,[...]. Gastroenterology 2015
49

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
46

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Parambir S Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr,[...]. Hepatology 2017
916
33

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias, Rolf Hultcrantz. Hepatology 2015
31


Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
30

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Rod S Taylor, Rebecca J Taylor, Sue Bayliss, Hannes Hagström, Patrik Nasr, Jorn M Schattenberg, Masatoshi Ishigami, Hidenori Toyoda, Vincent Wai-Sun Wong, Noam Peleg,[...]. Gastroenterology 2020
340
22

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Eduardo Vilar-Gomez, Luis Calzadilla-Bertot, Vincent Wai-Sun Wong, Marlen Castellanos, Rocio Aller-de la Fuente, Mayada Metwally, Mohammed Eslam, Licet Gonzalez-Fabian, María Alvarez-Quiñones Sanz, Antonio Felix Conde-Martin,[...]. Gastroenterology 2018
367
19

The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Paul Angulo, Jason M Hui, Giulio Marchesini, Ellisabetta Bugianesi, Jacob George, Geoffrey C Farrell, Felicity Enders, Sushma Saksena, Alastair D Burt, John P Bida,[...]. Hepatology 2007
19

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.
Amy G Shah, Alison Lydecker, Karen Murray, Brent N Tetri, Melissa J Contos, Arun J Sanyal. Clin Gastroenterol Hepatol 2009
812
17

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
17

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
Richard K Sterling, Eduardo Lissen, Nathan Clumeck, Ricard Sola, Mendes Cassia Correa, Julio Montaner, Mark S Sulkowski, Francesca J Torriani, Doug T Dieterich, David L Thomas,[...]. Hepatology 2006
16

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Siddharth Singh, Alina M Allen, Zhen Wang, Larry J Prokop, Mohammad H Murad, Rohit Loomba. Clin Gastroenterol Hepatol 2015
859
15

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
393
14

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Gastroenterology 2019
567
14

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
14

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
975
13

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
Quentin M Anstee, Eric J Lawitz, Naim Alkhouri, Vincent Wai-Sun Wong, Manuel Romero-Gomez, Takeshi Okanoue, Michael Trauner, Kathryn Kersey, Georgia Li, Ling Han,[...]. Hepatology 2019
134
12

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
Beth A Davison, Stephen A Harrison, Gad Cotter, Naim Alkhouri, Arun Sanyal, Christopher Edwards, Jerry R Colca, Julie Iwashita, Gary G Koch, Howard C Dittrich. J Hepatol 2020
126
12


The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Zobair M Younossi, Pegah Golabi, Leyla de Avila, James Minhui Paik, Manirath Srishord, Natsu Fukui, Ying Qiu, Leah Burns, Arian Afendy, Fatema Nader. J Hepatol 2019
708
11


Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
Ankur Srivastava, Ruth Gailer, Sudeep Tanwar, Paul Trembling, Julie Parkes, Alison Rodger, Deepak Suri, Douglas Thorburn, Karen Sennett, Sarah Morgan,[...]. J Hepatol 2019
191
11

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
Tracey G Simon, Bjorn Roelstraete, Hamed Khalili, Hannes Hagström, Jonas F Ludvigsson. Gut 2021
136
11


Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
653
10

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
10

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
Stuart McPherson, Stephen F Stewart, Elsbeth Henderson, Alastair D Burt, Christopher P Day. Gut 2010
535
10

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
Stefano Romeo, Julia Kozlitina, Chao Xing, Alexander Pertsemlidis, David Cox, Len A Pennacchio, Eric Boerwinkle, Jonathan C Cohen, Helen H Hobbs. Nat Genet 2008
10

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
Stuart McPherson, Tim Hardy, Jean-Francois Dufour, Salvatore Petta, Manuel Romero-Gomez, Mike Allison, Claudia P Oliveira, Sven Francque, Luc Van Gaal, Jörn M Schattenberg,[...]. Am J Gastroenterol 2017
341
10

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
Anna M Diehl, Christopher Day. N Engl J Med 2017
582
10

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, Heike Bantel, Stefano Bellentani, Joan Caballeria, Massimo Colombo, Antonio Craxi, Javier Crespo, Christopher P Day,[...]. J Hepatol 2018
672
10

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
Arun J Sanyal, Mark L Van Natta, Jeanne Clark, Brent A Neuschwander-Tetri, AnnaMae Diehl, Srinivasan Dasarathy, Rohit Loomba, Naga Chalasani, Kris Kowdley, Bilal Hameed,[...]. N Engl J Med 2021
133
10

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Stephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, Natalie Bzowej, Raj Vuppalanchi, Ziad Younes, Anita Kohli, Shiv Sarin, Stephen H Caldwell, Naim Alkhouri,[...]. J Hepatol 2020
183
9

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mustafa R Bashir, Cynthia D Guy, Rong Zhou, Cynthia A Moylan, Juan P Frias, Naim Alkhouri, Meena B Bansal, Seth Baum, Brent A Neuschwander-Tetri,[...]. Lancet 2019
238
9

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
Stuart McPherson, Tim Hardy, Elsbeth Henderson, Alastair D Burt, Christopher P Day, Quentin M Anstee. J Hepatol 2015
627
9

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
David E Kleiner, Elizabeth M Brunt, Laura A Wilson, Cynthia Behling, Cynthia Guy, Melissa Contos, Oscar Cummings, Matthew Yeh, Ryan Gill, Naga Chalasani,[...]. JAMA Netw Open 2019
147
9

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome,[...]. Lancet 2019
525
9

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
9

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
9

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Giovanni Targher, Christopher D Byrne, Amedeo Lonardo, Giacomo Zoppini, Corrado Barbui. J Hepatol 2016
681
9

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
Paul Angulo, Elisabetta Bugianesi, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Francisco Barrera, Svanhildur Haflidadottir, Christopher P Day, Jacob George. Gastroenterology 2013
325
9

The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
Leon A Adams, James F Lymp, Jenny St Sauver, Schuyler O Sanderson, Keith D Lindor, Ariel Feldstein, Paul Angulo. Gastroenterology 2005
9

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
9

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi, Arun J Sanyal. Hepatology 2018
924
9

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.
Zobair M Younossi, Maria Stepanova, Nila Rafiq, Hala Makhlouf, Zahra Younoszai, Ritambhara Agrawal, Zachary Goodman. Hepatology 2011
426
9

Epidemiology of chronic liver diseases in the USA in the past three decades.
Zobair M Younossi, Maria Stepanova, Youssef Younossi, Pegah Golabi, Alita Mishra, Nila Rafiq, Linda Henry. Gut 2020
180
9

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Philip N Newsome, Magali Sasso, Jonathan J Deeks, Angelo Paredes, Jérôme Boursier, Wah-Kheong Chan, Yusuf Yilmaz, Sébastien Czernichow, Ming-Hua Zheng, Vincent Wai-Sun Wong,[...]. Lancet Gastroenterol Hepatol 2020
219
8

Long-term follow-up of patients with NAFLD and elevated liver enzymes.
Mattias Ekstedt, Lennart E Franzén, Ulrik L Mathiesen, Lars Thorelius, Marika Holmqvist, Göran Bodemar, Stergios Kechagias. Hepatology 2006
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.